Nicotinic Immune Modulation in the Presence of HIV-1 Infection (R01)

Funding Agency:
National Institutes of Health

The FOA encourages the submission of research project applications to determine nicotine’s modulatory effects on peripheral and central immune system functions in the presence of HIV-1 infection.  Specifically, NIDA is particularly interested in projects exploring the ability of nicotine to produce anti-inflammatory and protective effects, and the translational potential of the new knowledge in attenuating HIV-induced pathologies and HIV-associated CNS complications such as neurological/cognitive disorders.   


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): January 17, 2017
  • AIDS Application Due Date(s): January 17, 2017

RFA-DA-17-020 Expiration Date January 18, 2017




Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

January 17, 2017